Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about a research setback in Huntington’s, big R&D investment at Boehringer, a Pfizer divestment in China, Lilly’s biomedicines plans, and the pandemic’s impact on launches and promotion.
Join us for an audio catch-up on the major events in the biopharma industry in the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 26 March 2021, including: a setback in Huntington’s; big R&D investment at Boehringer; a Pfizer divestment in China; Lilly’s biomedicines plans; and the pandemic’s impact on launches and promotion.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Roche Shelves Phase III Huntington's Candidate Tominersen" - Scrip, 23 Mar, 2021.)
(Also see "Boehringer Ingelheim Backs R&D With Big Bucks" - Scrip, 24 Mar, 2021.)
(Also see "Pfizer Throws In China Biosimilar Towel, Divests Site To WuXi" - Scrip, 19 Mar, 2021.)
(Also see "Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets" - Scrip, 22 Mar, 2021.)
(Also see "Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick" - Scrip, 24 Mar, 2021.)